Myomo MYO has been upgraded to a Zacks Rank 2 Buy , reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Is Myomo Inc. (MYO) Stock Down Today?
Updated Nov 22, 2026 6:19 AM ET ยท Prev Close $0.84
Session Regime & Catalyst Assessment
68% Signal ConvictionMyomo Inc. Pulling Back 3.45% on 1.36x Relative Volume
Myomo Inc. (MYO) is pulling back 3.45% (-$0.03) to $0.81 on 1.36x average session volume. Relative to benchmarks, MYO is trading in line with the S&P 500 (+0.19% alpha). 14-day RSI stands at 28.7, keeping momentum in a oversold regime.
Myomo MYO has been upgraded to a Zacks Rank 2 Buy , reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Price ($0.81) trades relative to 20-day SMA ($1.16) and 50-day SMA ($1.32).
Market & Sector Relative Strength
MYO trading in line with the S&P 500 (+0.19% alpha)Recent MYO Catalyst Headlines
Verified WireMyomo Nyseamerican Myo reported record third-quarter revenue of 12.3 million, up 22 from a year earlier, and narrowed its full-year revenue guidance as referrals and higher sales of its powered arm braces helped improve
Myomo Inc MYO posted record quarterly revenue of 12.3 million and roughly break-even adjusted EBITDA, while narrowing full-year guidance to 46- 47 million amid softer pipeline adds.
Moby summary of Myomo, Inc.'s Q3 2026 earnings call
1โ3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.80 (session support) for directional breakout confirmation.
Technical Regime (MYO)
BEARISH MA TRENDRetail & Crowd Sentiment
QuietA bullish StockTwits message expresses optimism regarding the history and future prospects of $MYO.
About Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes โฆ
Get Instant MYO Catalyst Alerts
Receive an email alert when MYO triggers an unusual volume breakout, options sweep, or rating shift.
MYO Session & Catalyst FAQ
Why is MYO stock down today?
Myomo Inc. (MYO) is pulling back 3.45% (-$0.03) to $0.81 on 1.36x average session volume. Relative to benchmarks, MYO is trading in line with the S&P 500 (+0.19% alpha). 14-day RSI stands at 28.7, keeping momentum in a oversold regime.
Is MYO stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.36x relative volume (moderate participation). Our multi-factor model currently rates MYO as HOLD. Review full valuation, quality, and timing signals on the MYO Buy or Sell Decision Brief โ
What is MYO's intrinsic value and expected trading range?
At $0.81, MYO's modeled 1-to-3 session range is $0.77 โ $0.85, with a key inflection level at $0.80 (session support). Compare current price against multi-year cash flow projections in the MYO Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for MYO?
RSI at 28.7 indicates oversold conditions โ watch for mean-reversion support. MYO trades at $0.81 relative to its 20-day SMA ($1.16) and 50-day SMA ($1.32), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.